Related references
Note: Only part of the references are listed.Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
Alejandra Gonzalez-Duarte et al.
JOURNAL OF NEUROLOGY (2020)
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
Teresa Coelho et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
David Adams et al.
NATURE REVIEWS NEUROLOGY (2019)
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study
Scott D. Solomon et al.
CIRCULATION (2019)
Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide
Sebastiaan H. C. Klaassen et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
Arnt V. Kristen et al.
PLOS ONE (2017)
Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness
Thibaud Damy et al.
EUROPEAN HEART JOURNAL (2016)
Hereditary ATTR amyloidosis: a single-institution experience with 266 patients
Paul L. Swiecicki et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2015)
Rapid progression of familial amyloidotic polyneuropathy A multinational natural history study
David Adams et al.
NEUROLOGY (2015)
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Ole B. Suhr et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Genotype, echocardiography, and survival in familial transthyretin amyloidosis
Adelaide M. Arruda-Olson et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2013)
Cardiac amyloidosis: Updates in diagnosis and management
Dania Mohty et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2013)
THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
Teresa Coelho et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective
Claudio Rapezzi et al.
EUROPEAN HEART JOURNAL (2013)
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Yukio Ando et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)
Frederick L. Ruberg et al.
AMERICAN HEART JOURNAL (2012)
Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant
Prayman T. Sattianayagam et al.
EUROPEAN HEART JOURNAL (2012)
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho et al.
NEUROLOGY (2012)
Share Paper
